Denali Historical Balance Sheet

DNLI Stock

USD 13.81 0.31 2.20%

Trend analysis of Denali Therapeutics balance sheet accounts such as Total Current Liabilities of 120.9 M or Total Stockholder Equity of 776.9 M provides information on Denali Therapeutics' total assets, liabilities, and equity, which is the actual value of Denali Therapeutics to its prevalent stockholders. By breaking down trends over time using Denali Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Denali Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Denali Therapeutics is a good buy for the upcoming year.

Denali Therapeutics Inventory

1.21

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

About Denali Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Denali Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Denali Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Denali Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Denali currently owns. An asset can also be divided into two categories, current and non-current.

Denali Therapeutics Balance Sheet Chart

As of now, Denali Therapeutics' Accounts Payable is increasing as compared to previous years. The Denali Therapeutics' current Cash is estimated to increase to about 194.3 M, while Total Assets are projected to decrease to under 990.7 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Common Stock Shares Outstanding

Add Fundamental

Total Assets

Total assets refers to the total amount of Denali Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Denali Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Denali Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Denali Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Denali Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.As of now, Denali Therapeutics' Accounts Payable is increasing as compared to previous years. The Denali Therapeutics' current Cash is estimated to increase to about 194.3 M, while Total Assets are projected to decrease to under 990.7 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	63.8M	61.2M	91.1M	95.6M
Total Assets	1.5B	1.2B	1.4B	990.7M

Other Current Liab Total Assets

Denali Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Total Assets		0.82	0.73	0.99	0.42	0.97	0.82	-0.74	-0.76	0.52	0.83	0.64	0.38	0.54	0.97	0.67	0.93	0.44	0.95	0.94	0.87	0.84	0.74	0.79	0.97	0.69
Other Current Liab	0.82		0.59	0.84	0.04	0.8	0.94	-0.43	-0.98	0.86	0.55	0.78	0.77	0.2	0.76	0.57	0.83	0.1	0.93	0.84	0.98	0.57	0.96	0.55	0.77	0.59
Total Current Liabilities	0.73	0.59		0.65	-0.04	0.65	0.53	-0.43	-0.54	0.27	0.52	0.54	0.14	0.84	0.67	0.41	0.64	0.03	0.67	0.75	0.6	0.82	0.42	0.47	0.68	0.43
Total Stockholder Equity	0.99	0.84	0.65		0.37	0.98	0.84	-0.69	-0.81	0.6	0.78	0.66	0.44	0.45	0.95	0.71	0.94	0.37	0.95	0.94	0.89	0.74	0.78	0.83	0.95	0.73
Other Liab	0.42	0.04	-0.04	0.37		0.38	0.17	-0.73	0.08	-0.25	0.71	-0.04	-0.14	0.09	0.51	0.2	0.27	0.97	0.25	0.19	0.12	0.51	0.06	0.3	0.5	0.19
Net Tangible Assets	0.97	0.8	0.65	0.98	0.38		0.8	-0.7	-0.78	0.56	0.78	0.6	0.38	0.48	0.94	0.58	0.94	0.4	0.94	0.94	0.85	0.76	0.74	0.77	0.94	0.6
Property Plant And Equipment Net	0.82	0.94	0.53	0.84	0.17	0.8		-0.43	-0.93	0.8	0.56	0.81	0.75	0.22	0.75	0.61	0.88	0.22	0.93	0.85	0.95	0.59	0.97	0.64	0.75	0.63
Net Debt	-0.74	-0.43	-0.43	-0.69	-0.73	-0.7	-0.43		0.28	-0.09	-0.98	-0.35	-0.11	-0.33	-0.76	-0.41	-0.48	-0.7	-0.61	-0.49	-0.44	-0.75	-0.33	-0.52	-0.76	-0.4
Retained Earnings	-0.76	-0.98	-0.54	-0.81	0.08	-0.78	-0.93	0.28		-0.91	-0.41	-0.77	-0.79	-0.18	-0.69	-0.56	-0.84	0.04	-0.9	-0.84	-0.97	-0.45	-0.96	-0.58	-0.7	-0.59
Accounts Payable	0.52	0.86	0.27	0.6	-0.25	0.56	0.8	-0.09	-0.91		0.19	0.76	0.85	-0.12	0.42	0.42	0.64	-0.22	0.73	0.64	0.84	0.14	0.9	0.38	0.43	0.45
Cash	0.83	0.55	0.52	0.78	0.71	0.78	0.56	-0.98	-0.41	0.19		0.43	0.17	0.38	0.85	0.48	0.61	0.71	0.72	0.61	0.56	0.83	0.46	0.59	0.85	0.47
Non Current Assets Total	0.64	0.78	0.54	0.66	-0.04	0.6	0.81	-0.35	-0.77	0.76	0.43		0.78	0.27	0.47	0.53	0.68	-0.03	0.76	0.73	0.79	0.46	0.79	0.52	0.48	0.53
Non Currrent Assets Other	0.38	0.77	0.14	0.44	-0.14	0.38	0.75	-0.11	-0.79	0.85	0.17	0.78		-0.2	0.27	0.31	0.46	-0.13	0.58	0.46	0.72	0.1	0.83	0.22	0.27	0.32
Other Assets	0.54	0.2	0.84	0.45	0.09	0.48	0.22	-0.33	-0.18	-0.12	0.38	0.27	-0.2		0.51	0.31	0.47	0.09	0.42	0.55	0.29	0.71	0.05	0.46	0.52	0.33
Cash And Short Term Investments	0.97	0.76	0.67	0.95	0.51	0.94	0.75	-0.76	-0.69	0.42	0.85	0.47	0.27	0.51		0.62	0.87	0.52	0.9	0.86	0.81	0.85	0.67	0.73	1.0	0.65
Common Stock Total Equity	0.67	0.57	0.41	0.71	0.2	0.58	0.61	-0.41	-0.56	0.42	0.48	0.53	0.31	0.31	0.62		0.62	0.1	0.62	0.6	0.63	0.4	0.56	0.89	0.62	1.0
Common Stock Shares Outstanding	0.93	0.83	0.64	0.94	0.27	0.94	0.88	-0.48	-0.84	0.64	0.61	0.68	0.46	0.47	0.87	0.62		0.31	0.94	0.98	0.9	0.69	0.82	0.77	0.87	0.64
Non Current Liabilities Total	0.44	0.1	0.03	0.37	0.97	0.4	0.22	-0.7	0.04	-0.22	0.71	-0.03	-0.13	0.09	0.52	0.1	0.31		0.27	0.24	0.15	0.59	0.11	0.21	0.52	0.09
Capital Surpluse	0.95	0.93	0.67	0.95	0.25	0.94	0.93	-0.61	-0.9	0.73	0.72	0.76	0.58	0.42	0.9	0.62	0.94	0.27		0.94	0.96	0.73	0.89	0.73	0.9	0.65
Other Current Assets	0.94	0.84	0.75	0.94	0.19	0.94	0.85	-0.49	-0.84	0.64	0.61	0.73	0.46	0.55	0.86	0.6	0.98	0.24	0.94		0.9	0.74	0.79	0.73	0.86	0.62
Other Stockholder Equity	0.87	0.98	0.6	0.89	0.12	0.85	0.95	-0.44	-0.97	0.84	0.56	0.79	0.72	0.29	0.81	0.63	0.9	0.15	0.96	0.9		0.61	0.95	0.64	0.82	0.66
Total Liab	0.84	0.57	0.82	0.74	0.51	0.76	0.59	-0.75	-0.45	0.14	0.83	0.46	0.1	0.71	0.85	0.4	0.69	0.59	0.73	0.74	0.61		0.45	0.49	0.85	0.41
Property Plant And Equipment Gross	0.74	0.96	0.42	0.78	0.06	0.74	0.97	-0.33	-0.96	0.9	0.46	0.79	0.83	0.05	0.67	0.56	0.82	0.11	0.89	0.79	0.95	0.45		0.56	0.67	0.58
Preferred Stock Total Equity	0.79	0.55	0.47	0.83	0.3	0.77	0.64	-0.52	-0.58	0.38	0.59	0.52	0.22	0.46	0.73	0.89	0.77	0.21	0.73	0.73	0.64	0.49	0.56		0.74	0.89
Total Current Assets	0.97	0.77	0.68	0.95	0.5	0.94	0.75	-0.76	-0.7	0.43	0.85	0.48	0.27	0.52	1.0	0.62	0.87	0.52	0.9	0.86	0.82	0.85	0.67	0.74		0.65
Common Stock	0.69	0.59	0.43	0.73	0.19	0.6	0.63	-0.4	-0.59	0.45	0.47	0.53	0.32	0.33	0.65	1.0	0.64	0.09	0.65	0.62	0.66	0.41	0.58	0.89	0.65

Click cells to compare fundamentals

Denali Therapeutics Account Relationship Matchups

Denali Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.6B	1.4B	1.5B	1.2B	1.4B	990.7M
Other Current Liab	42.5M	47.7M	63.8M	61.2M	91.1M	95.6M
Total Current Liabilities	71.7M	378.2M	363.9M	78.0M	102.2M	120.9M
Total Stockholder Equity	1.2B	962.3M	1.0B	1.0B	1.2B	776.9M
Other Liab	44.1M	317.9M	5.1M	858K	986.7K	937.4K
Net Tangible Assets	394.9M	1.2B	962.3M	1.0B	1.2B	612.3M
Property Plant And Equipment Net	73.5M	69.6M	74.5M	71.6M	125.6M	131.9M
Net Debt	(443.0M)	(234.9M)	(157.7M)	(74.9M)	(132.7M)	(139.3M)
Retained Earnings	(354.4M)	(645.0M)	(971.0M)	(1.1B)	(1.5B)	(1.5B)
Accounts Payable	1.1M	4.8M	2.8M	9.5M	11.1M	11.7M
Cash	507.1M	293.5M	218.0M	127.1M	175.0M	194.3M
Non Current Assets Total	108.6M	506.9M	87.9M	89.8M	509.7M	535.2M
Non Currrent Assets Other	2.5M	11.9M	11.9M	18.1M	384.1M	403.3M
Other Assets	2.5M	11.9M	13.4M	1.0	1.15	1.09
Cash And Short Term Investments	1.5B	865.4M	1.3B	1.0B	832.3M	773.6M
Common Stock Shares Outstanding	112.7M	121.5M	125.5M	137.4M	164.5M	96.2M
Liabilities And Stockholders Equity	1.6B	1.4B	1.5B	1.2B	1.4B	990.7M
Non Current Liabilities Total	382.1M	63.6M	53.9M	45.0M	42.3M	40.2M
Capital Surpluse	774.2M	818.8M	1.5B	1.6B	1.8B	1.9B
Other Current Assets	20.3M	30.6M	26.8M	26.2M	32.1M	19.4M
Other Stockholder Equity	1.5B	1.6B	2.0B	2.1B	2.8B	2.9B
Total Liab	453.7M	441.9M	417.8M	123.0M	144.5M	213.9M
Property Plant And Equipment Gross	73.5M	69.6M	74.5M	117.6M	177.7M	186.6M
Total Current Assets	1.5B	897.2M	1.4B	1.1B	864.4M	795.3M
Accumulated Other Comprehensive Income	(245K)	(2.5M)	(6.9M)	643K	2.0M	2.1M
Common Stock	1.5M	1.5M	1.7M	1.7M	1.8M	1.6M
Property Plant Equipment	80.7M	40.8M	69.6M	74.5M	85.7M	44.6M
Short Term Investments	962.6M	571.9M	1.1B	907.4M	657.4M	643.7M
Long Term Investments	39.9M	32.7M	425.4M	0.0	359.4M	377.3M
Non Current Liabilities Other	471K	379K	382.1M	5.6M	6.5M	6.1M
Net Invested Capital	1.2B	962.3M	1.0B	1.0B	1.2B	938.2M
Net Working Capital	1.4B	519.0M	1.0B	986.2M	762.2M	815.1M
Current Deferred Revenue	23.5M	320.3M	290.1M	(46.9M)	(53.9M)	(51.2M)
Capital Stock	1.5M	1.5M	1.7M	1.7M	1.8M	1.7M
Short Term Debt	4.7M	5.5M	7.3M	7.3M	6.5M	6.3M
Short Long Term Debt Total	64.2M	58.6M	60.4M	52.2M	42.3M	46.2M

Currently Active Assets on Macroaxis

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria
HMY	Harmony Gold Mining
FSM	Fortuna Silver Mines

When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:

How To Invest In Denali

Details

Is Denali Stock a good investment?

Details

What is Denali Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.57)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.25)

Return On Equity

(0.37)

The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Denali Historical Balance Sheet

Denali Therapeutics Inventory

1.21

About Denali Balance Sheet Analysis

Denali Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Common Stock Shares Outstanding

Denali Therapeutics balance sheet Correlations

Denali Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Denali Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.98	Other Current Liab
Net Tangible Assets	+ 0.98	Total Stockholder Equity
Other Current Assets	+ 0.98	Common Stock Shares Outstanding

Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Other Current Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.93	Property Plant And Equipment Net
Accounts Payable	- 0.91	Retained Earnings